Evaluation of the efficacy and safety of anti-allergic ophthalmic solution for the treatment of allergic conjunctivitis.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 28 Apr 2015
Price : $35 *
At a glance
- Drugs Epinastine (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 28 Apr 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 10 Mar 2014 New trial record